Condition
seasonal allergic rhinitis and/or rhinoconjunctivitis
Total Trials
1
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
Treatment Research
2 treatments under study, led by Pollinex Quattro Plus 10 Ml Birch
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
100%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 3 (1)
Trial Status
Not Yet Recruiting1
Clinical Trials (1)
Research Network
Common Treatments
- Pollinex Quattro Plus 10 Ml Birch1
- Placebo 2 Wv Ltyrosine And 05 Wv Phenol For Subcutaneous Use1
Active Sponsors
- Allergy Therapeutics (UK) Limited1